Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | L. Najmi, PhD Thesis, 2018, University of Bergen | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | oligonucleotide | DOTAP | publication | A. Avinó et al., Protocols in Nucleic Acid Chemistry, 2020, 77: e78, doi: 10.1002/cpnc.78 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | M. R. Spinosa et al., J. Neurosci., Feb 2008; 28: 1640 - 1648 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | Metafectene | publication | N. Cidlinsky et al., Cell Oncol., 2016, 39:389-396; DOI 10.1007/s13402-016-0290-8 | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | P. Hubel et al., Nature Immunology, 2019, 20: 493–502, https://doi.org/10.1038/s41590-019-0323-3. | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | S. Gebremedhin et al., Biophysical J., 2014, 106(2): 625a | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | R. Romano et al., Cell. and Mol. Life Sci., 2021, 78: 351–372, 78:351–372, doi.org/10.1007/s00018-020-03510-1 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., J. Lipid Res., Nov 2008; 49: 2312 - 2322 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. Stretton et al., Biochem. J., Sep 2015; 470: 207 - 221 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | K. Wethmar et al., Oncogene, 2016, 35,1736-1742; doi:10.1038/onc.2015.233 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | W. Kim et al., J. Biol. Chem., 287 (8): 5278–5289, DOI 10.1074/jbc.M111.281709 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | T. Sasazuki et al., J. Biol. Chem., Aug 2002; 277: 28853 - 28860 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | A. Raturi et al., J. Cell Biol., Aug 2016; 214, 433 - 444 | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene EASY | publication | R. Hrdlickova et al., PLoS ONE, 2014, 9(2): e86990, doi:10.1371/journal.pone.0086990 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | Y. P. Abudu et al., J. Cell Biol., 2021, 220(8): e202009092, doi: 10.1083/jcb.202009092 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. T. Hellwig et al., J. Cell Sci., May 2010; 123: 1401 - 1406 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene EASY | publication | E. Roscioli et al., J. Cell Biol., Feb 2012; 196: 435 - 450 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene PRO | publication | M. De Luca et al., J. Cell Sci., Jun 2014; 127: 2697 - 2708 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | miRNA | Metafectene PRO | publication | S. Demir, Master Thesis, 2012, Izmir Institute of Technology | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. G. Theis et al., PNAS, Aug 2004; 101: 11221 - 11226 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. C. Mayer et al., J. Immunol., Oct 2013; 191: 3594 - 3604 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | K. Estrada, JAMA, 2014, 311(22): 2305-2314; doi:10.1001/jama.2014.6511 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. Neumann-Giesen et al., J. Cell Sci., Feb 2007; 120: 395 - 406 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | D.W. Chen et al., In: C. Boon, J. Wijnholds (eds) Retinal Gene Therapy. Methods in Molecular Biology, 2018, 1715, Humana Press, NY |